Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.

CONCLUSIONS: This TIM-3 and PD-L1 bispecific format was associated with unexpected immunogenicity targeting both arms of the bispecific antibody, resulting in early study termination. Epitope specificity analysis revealed an initial response towards the TIM-3 arm and presence of pre‑existing ADAs to the bispecific molecule in the general population. This experience emphasizes the importance of thorough analyses for pre‑existing ADAs as part of immunogenicity risk assessment of novel antibodies.
PMID: 33441294 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 13, 2021 Category: Cancer & Oncology Authors: Hellmann MD, Bivi N, Calderon B, Shimizu T, Delafontaine B, Liu ZT, Szpurka AM, Copeland V, Hodi FS, Rottey S, Aftimos P, Piao Y, Gandhi L, Galvao VR, Leow CC, Doi T Tags: Clin Cancer Res Source Type: research